| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
WBIO Stock Overview
Wockhardt Bio AG, together with its subsidiaries, develops, manufactures, and markets pharmaceutical and bio-pharmaceutical formulations in the United States, the United Kingdom, Ireland, France, other European countries, the Middle East, Latin America, and internationally.
Wockhardt Bio Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF1.51 |
| 52 Week High | CHF3.26 |
| 52 Week Low | CHF0.85 |
| Beta | -10.8 |
| 1 Month Change | -10.12% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | 619.05% |
| 5 Year Change | n/a |
| Change since IPO | -70.10% |
Recent News & Updates
Shareholder Returns
| WBIO | CH Biotechs | CH Market | |
|---|---|---|---|
| 7D | 0% | 1.3% | 0.08% |
| 1Y | n/a | -14.1% | -12.9% |
Return vs Industry: Insufficient data to determine how WBIO performed against the Swiss Biotechs industry.
Return vs Market: Insufficient data to determine how WBIO performed against the Swiss Market.
Price Volatility
| WBIO volatility | |
|---|---|
| WBIO Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 13.0% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in CH Market | 7.8% |
| 10% least volatile stocks in CH Market | 2.4% |
Stable Share Price: Insufficient data to determine WBIO's volatility over the past 3 months.
Volatility Over Time: Insufficient data to determine WBIO's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 50 | n/a | https://www.wockhardtbio.com |
Wockhardt Bio AG, together with its subsidiaries, develops, manufactures, and markets pharmaceutical and bio-pharmaceutical formulations in the United States, the United Kingdom, Ireland, France, other European countries, the Middle East, Latin America, and internationally. The company’s products cover various therapeutic categories, including central nervous system agents, hormones and related agents, cardiovascular agents, anti-infective agents, and respiratory agents, as well as other agents, such as gastrointestinal, dermatological, and biological (vaccines) agents. It also exports its products to approximately 50 countries worldwide.
Wockhardt Bio Fundamentals Summary
| WBIO fundamental statistics | |
|---|---|
| Market Cap | CHF78.44m |
| Earnings (TTM) | -CHF2.82m |
| Revenue (TTM) | CHF282.39m |
0.3x
P/S Ratio-27.8x
P/E RatioIs WBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| WBIO income statement (TTM) | |
|---|---|
| Revenue | US$297.12m |
| Cost of Revenue | US$133.64m |
| Gross Profit | US$163.48m |
| Other Expenses | US$166.45m |
| Earnings | -US$2.97m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.057 |
| Gross Margin | 55.02% |
| Net Profit Margin | -1.00% |
| Debt/Equity Ratio | 21.1% |
How did WBIO perform over the long term?
See historical performance and comparisonValuation
Is WBIO undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast
Key Valuation Metric
Which metric is best to use when looking at relative valuation for WBIO?
Other financial metrics that can be useful for relative valuation.
| What is WBIO's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | US$82.53m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.3x |
| Enterprise Value/EBITDA | 100.6x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does WBIO's PS Ratio compare to its peers?
| WBIO PS Ratio vs Peers |
|---|
| Company | PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 13.8x | ||
BSLN Basilea Pharmaceutica | 3.2x | 11.5% | CHF476.9m |
KURN Kuros Biosciences | 3.9x | n/a | CHF58.7m |
ADXN Addex Therapeutics | 5.2x | -79.1% | CHF12.9m |
RLF Relief Therapeutics Holding | 41.6x | 53.2% | CHF137.1m |
WBIO Wockhardt Bio | 0.3x | n/a | CHF78.4m |
Price-To-Sales vs Peers: WBIO is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (13.8x).
Price to Earnings Ratio vs Industry
How does WBIO's PE Ratio compare vs other companies in the European Biotechs Industry?
Price-To-Sales vs Industry: WBIO is good value based on its Price-To-Sales Ratio (0.3x) compared to the Swiss Biotechs industry average (4.1x)
Price to Sales Ratio vs Fair Ratio
What is WBIO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.3x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate WBIO's Price-To-Sales Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of WBIO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: WBIO (CHF1.51) is trading below our estimate of fair value (CHF27.5)
Significantly Below Fair Value: WBIO is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Future Growth
How is Wockhardt Bio forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
40.1%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Wockhardt Bio has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine whether Wockhardt Bio is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
- Wockhardt Bio competitive advantages and company strategy can generally be found in its financial reports archived here.
Past Performance
How has Wockhardt Bio performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
48.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: WBIO is currently unprofitable.
Growing Profit Margin: WBIO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: WBIO is unprofitable, but has reduced losses over the past 5 years at a rate of 48.8% per year.
Accelerating Growth: Unable to compare WBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: WBIO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-12.1%).
Return on Equity
High ROE: WBIO has a negative Return on Equity (-1.06%), as it is currently unprofitable.
Discover strong past performing companies
Financial Health
How is Wockhardt Bio's financial position?
Financial Health Score
4/6Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: WBIO's short term assets ($308.1M) do not cover its short term liabilities ($317.5M).
Long Term Liabilities: WBIO's short term assets ($308.1M) exceed its long term liabilities ($33.1M).
Debt to Equity History and Analysis
Debt Level: WBIO's net debt to equity ratio (7.4%) is considered satisfactory.
Reducing Debt: WBIO's debt to equity ratio has reduced from 103.8% to 21.1% over the past 5 years.
Debt Coverage: WBIO's debt is well covered by operating cash flow (111.6%).
Interest Coverage: Insufficient data to determine if WBIO's interest payments on its debt are well covered by EBIT.
Balance Sheet
Discover healthy companies
Dividend
What is Wockhardt Bio current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate WBIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate WBIO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if WBIO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if WBIO's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: WBIO is not paying a notable dividend for the Swiss market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as WBIO has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
3.3yrs
Average board tenure
CEO
Wockhardt Bio has no CEO, or we have no data on them.
Board Members
Experienced Board: WBIO's board of directors are considered experienced (3.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Wockhardt Bio AG's employee growth, exchange listings and data sources
Key Information
- Name: Wockhardt Bio AG
- Ticker: WBIO
- Exchange: BRSE
- Founded: NaN
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: CHF78.441m
- Shares outstanding: 51.95m
- Website: https://www.wockhardtbio.com
Number of Employees
Location
- Wockhardt Bio AG
- Grafenauweg 6
- Zug
- Zug
- 6300
- Switzerland
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/08/16 00:00 |
| End of Day Share Price | 2022/08/05 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2022/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.